Watch the video and download the slides
Hemato-oncology
The Role of PI3K inhibitors in NHL
Dr. Tycel J. Phillips discusses the Role of PI3K inhibitors in Non-Hodgkin’s Lymphoma
Publication Date
Sep 2021
Dr Tycel Phillips, is a lymphoma specialist with a research and clinical focus on non-hodgkin lymphoma. Dr Phillips completed his hematology-oncology fellowship at University Hospitals/Case Western University. While at Case Western, Dr Phillips began to focus on the development of clinical trials utilizing novel agents in lymphoma. He has continued his focus on clinical research upon his appointment at the University of Michigan and in addition has been the site primary investigator on numerous clinical trials in multiple subtypes of lymphoma. Dr Phillips’s research interests include evaluation of resistance mechanisms in mantle cell lymphoma (MCL), non-cytotoxic chemotherapeutic treatment in frontline MCL, and other novel combinations in relapsed/refractory lymphoma. Dr Phillips is involved in professional societies including the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).
Programme summary
Duration 5 MIN
Downloadable resources Yes-
DOWNLOAD THE SLIDES
-
Language(s)
Share this programme
Brought to you by
LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Karyopharm Therapeutics and Menarini Stemline Oncology.
Meet the experts
Other programmes of interest
Video
Oncology Hemato-oncology
Early relapsed/refractory multiple myeloma (RRMM): best practices in management
A 3-part video series on managing early RRMM from leading medical experts
Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael-
Downloadable
Resources -
4 MIN
-
Sep 2024
Oncology Hemato-oncology
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)
Medical experts discuss the latest learnings from clinical practice
Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter-
Downloadable
Resources -
MIN
-
Jun 2024
Conference update
Episode
6
of 6
Oncology Hemato-oncology
Listen to Expert Insights on Late-Breaking Data from ASCO 2023
Episode 6: Lymphoma Update: SWOG S1826 trial
Experts
Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager-
2 MIN
-
Jun 2023
Oncology Hemato-oncology
Update From ASH 2022
Highlights from the ASH Annual Meeting
Experts
Dr Matthew J. Matasar-
4 MIN
-
Dec 2022
Hemato-oncology
Update from ASCO 2022 – Myeloma
Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)
Experts
Asst. Prof. Hans Lee-
2 MIN
-
May 2022
Podcast
Episode
3
of 3
Hemato-oncology
Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics
Experts
Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin-
Downloadable
Resources -
MIN
-
Mar 2022
